Optimal Individualized Combination Immunotherapy/Oncolytic Virotherapy Determined Through In Silico Clinical Trials Improves Late Stage Melanoma Patient Outcomes

摘要: Abstract Oncolytic virothcrapics, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects. The OPTiM trial in particular demonstrated superior anti-cancer effects T-VEC compared to more traditional immunotherapy treatment using exogenous administration granulocyte-macrophage colony-stimulating factor (GM-CSF). Theoretically, a combined approach leveraging immunotherapies: like cytokine and oncolytic virotherapv would elicit an even greater response improve patient outcomes, but given that their efficacy safety must be tested large clinical trials, combination therapeutic regimens yet established. By adopting computational biology silico approaches, here we show significantly improved outcomes for individuals with late-stage melanoma by personalizing optimizing oncolytic, GM-CSF therapy. Our results serve proof-of-concept, interdisciplinary approaches determining therapy, suggest promising avenues investigation towards tailored immunotherapy/oncolytic virotherapy.